Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» hemophilia A
hemophilia A
BioMarin tries to get hemophilia gene therapy back on track with positive data
BioMarin tries to get hemophilia gene therapy back on track with positive data
BioPharma Dive
Biomarin
hemophilia A
gene therapy
clinical trials
Roctavian
Flag link:
#ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $4.5B buyout
#ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $4.5B buyout
Endpoints
ASH2020
uniQure
hemophilia A
Sangamao
gene therapy
Biomarin
Flag link:
How BioMarin Beat Expectations in Q3
How BioMarin Beat Expectations in Q3
Motley Fool
Biomarin
hemophilia A
earnings
Flag link:
Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment SB-525
Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment SB-525
Drugs.com
Pfizer
Sangamo Therapeutics
genomics
clinical trials
hemophilia A
giroctocogene fitelparvovec
SB-525
Flag link:
Sanofi's hemophilia drug comes into focus as delays hit a key competitor
Sanofi's hemophilia drug comes into focus as delays hit a key competitor
BioPharma Dive
Sanofi
hemophilia
hemophilia A
BIVV001
Flag link:
Is valrox dead?
Is valrox dead?
EP Vantage
Biomarin
hemophilia A
valrox
gene therapy
Roche
Pfizer
FDA
Flag link:
FDA gets out its red pen again, rejecting BioMarin's gene therapy valrox amid durability worries
FDA gets out its red pen again, rejecting BioMarin's gene therapy valrox amid durability worries
Fierce Biotech
Biomarin
FDA
valrox
hemophilia A
Flag link:
Roche targets 2021 start for hemophilia A gene therapy phase 3 as optimization effort drags on
Roche targets 2021 start for hemophilia A gene therapy phase 3 as optimization effort drags on
Fierce Biotech
Roche
hemophilia A
Spark Therapeutics
SPK-8011
Flag link:
Pfizer, Sangamo flesh out hemophilia gene therapy data ahead of phase 3
Pfizer, Sangamo flesh out hemophilia gene therapy data ahead of phase 3
Fierce Biotech
Pfizer
Sangamo BioSciences
hemophilia A
clinical trials
gene therapy
giroctocogene fitelparvovec
Flag link:
BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment
BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment
BioSpace
Biomarin
clinical trials
hemophilia A
valoctocogene roxaparvovec
Flag link:
BioMarin gene therapy shows sustained benefit in hemophilia A study
BioMarin gene therapy shows sustained benefit in hemophilia A study
Seeking Alpha
Biomarin
hemophilia A
clinical trials
gene therapy
valoctocogene roxaparvovec
Flag link:
Regeneron to expand development deal with Intellia Therapeutics
Regeneron to expand development deal with Intellia Therapeutics
Marketwatch
Regeneron
Intellia Therapeutics
hemophilia A
hemophilia B
CRISPR
drug development
Flag link:
BioMarin's Novel Treatment Promises to Disrupt Competitors
BioMarin's Novel Treatment Promises to Disrupt Competitors
Motley Fool
Biomarin
gene therapy
valrox
hemophilia A
Flag link:
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review
Motley Fool
FDA
Biomarin
priority review
valrox
gene therapy
hemophilia A
Flag link:
Novimmune unit nabs Takeda milestone payment for hemophilia work
Novimmune unit nabs Takeda milestone payment for hemophilia work
Fierce Biotech
Takeda
Light Chain Bioscience
Novimmune
R&D
Hemlibra
hemophilia A
Flag link:
Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World
Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World
Forbes
Biomarin
valrox
gene therapy
hemophilia A
Flag link:
Takeda Eyes 12 New Drug Approvals by 2024, Hemophilia Gene Therapy May Not be a Competitor
Takeda Eyes 12 New Drug Approvals by 2024, Hemophilia Gene Therapy May Not be a Competitor
BioSpace
Takeda
drug approvals
hemophilia A
TAK-754
TAK-748
Flag link:
Generation Bio grabs a $110M round to ramp up work on next-gen gene therapies
Generation Bio grabs a $110M round to ramp up work on next-gen gene therapies
Fierce Biotech
Generation Bio
hemophilia A
phenylketonuria
gene therapies
Flag link:
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Biopharma Dive
Biomarin
hemophilia
hemophilia A
gene therapy
valoctocogene roxaparvovec
uniQure
hemophilia B
etranadez
Flag link:
Sigilon Therapeutics approaches the clinic
Sigilon Therapeutics approaches the clinic
EP Vantage
Sigilon
orphan drug
hemophilia A
Eli Lilly
diabetes
Flag link:
Pages
1
2
3
4
next ›
last »